Business context and reporting period
The filing is a Form 10-Q for the quarter and nine months ended September 30, 2023. Although the request metadata names Gridai Technologies Corp., the filing identifies the registrant as First Wave BioPharma, Inc. (Nasdaq: FWBI); verify the intended company and filing.
First Wave is a pre-revenue biotechnology company developing gastrointestinal therapies: Adrulipase, Capeserod and Niclosamide. Its financial statements are unaudited.
Financial results and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development | $1.01 million in 2023; $0.79 million in 2022 | $3.73 million in 2023; $8.67 million in 2022 |
| General and administrative | $2.42 million in 2023; $2.90 million in 2022 | $7.95 million in 2023; $9.81 million in 2022 |
| Net income (loss) | $(3.43) million in 2023; $4.39 million in 2022 | $(11.69) million in 2023; $(10.64) million in 2022 |
| Operating cash flow | Not presented for the quarter | $(8.94) million per cash flow statement |
The 2022 quarterly profit reflected an $8.09 million research and development recovery related to a reduction in acquisition-related liabilities, rather than recurring operating performance. The nine-month comparison is also affected by that prior-period recovery. Margins are not meaningful because the company reported no revenue.
At September 30, cash and cash equivalents were $3.29 million, restricted cash was about $0.02 million, and working capital was about $1.49 million. Current assets were $3.98 million versus current liabilities of $2.48 million. The company reported no note payable outstanding; liabilities included operating lease obligations of about $0.23 million. Stockholders’ equity was $3.28 million, and accumulated deficit was $180.23 million.
Financing activities provided $10.87 million in the first nine months, primarily from stock and warrant transactions; cash increased by $1.93 million. The company issued substantial equity and warrants: common shares outstanding rose from 995,003 at December 31, 2022 to 13,463,479 at September 30, 2023. It reported 17,972,611 outstanding warrants at quarter-end.
Changes, outlook and material risks
- Management said available cash was expected to fund planned operations only through December 2023. The filing states that recurring losses and operating cash outflows create substantial doubt about the company’s ability to continue as a going concern without additional financing.
- Management expects research and development expense to decline as it closes out the Adrulipase Phase 2b SPAN trial, and general and administrative expense to remain stable for the rest of 2023. No formal financial guidance was provided.
- Adrulipase’s July 2023 Phase 2b topline results indicated the primary efficacy endpoint was likely not achieved, although the formulation was reported safe and well tolerated. The company planned to assess further data and seek an FDA Type C meeting in 2024.
- In September 2023, the company licensed Capeserod from Sanofi for gastrointestinal development. The agreement includes a $500,000 upfront payment, up to $46 million in development and regulatory milestones, up to $235 million in commercial milestones, royalties and other potential payments. The company expected to pursue a Phase 2 program in pediatric ulcerative colitis or gastroparesis.
- Niclosamide development was constrained: the COVID-19 gastrointestinal program was discontinued after mixed results, resources for the ulcerative proctitis/proctosigmoiditis program were reduced, and the ICI-associated colitis program was on hold due to financial constraints.
- Nasdaq had notified the company of noncompliance with the minimum stockholders’ equity and minimum bid-price requirements. A later notice cited a shareholder-approval issue related to the July 2023 offering. Failure to regain compliance could result in delisting. The company also disclosed risks around financing, clinical and regulatory success, manufacturing, intellectual property, vendors and its Sanofi license obligations.
- A former director’s advancement-of-legal-fees case was decided in the company’s favor; the court denied the former director’s request to reargue or amend. Management reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter.
Investor verification points
- Confirm the issuer: the supplied metadata says Gridai Technologies Corp., but the filing is for First Wave BioPharma, Inc. (FWBI).
- Verify the cash-flow presentation: the cash flow statement reports $8.94 million of operating cash used, while the MD&A cash-flow table gives $8.44 million and describes investing cash use differently. Reconcile these figures against the filed statements and XBRL.
- Check actual cash runway and financing needs after September 30, 2023, including whether further capital was raised and whether operations continued as planned beyond the stated December 2023 runway.
- Track Nasdaq compliance notices and the company’s ability to meet equity, bid-price and shareholder-approval requirements.
- Assess dilution and warrant overhang, including the terms and potential exercise of the 17.97 million warrants outstanding at quarter-end.
- Review subsequent clinical updates for Adrulipase and Capeserod, and any implications for Sanofi milestone, royalty or license obligations.